- Home
- VTR vs BIIB Comparison
VTR vs BIIB Comparison
Compare VTR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTR
- BIIB
- Stock Information
- Founded
- VTR 1983
- BIIB 1978
- Country
- VTR United States
- BIIB United States
- Employees
- VTR N/A
- BIIB N/A
- Industry
- VTR Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- VTR Real Estate
- BIIB Health Care
- Exchange
- VTR Nasdaq
- BIIB Nasdaq
- Market Cap
- VTR 27.3B
- BIIB 25.1B
- IPO Year
- VTR 1998
- BIIB 1991
- Fundamental
- Price
- VTR $60.72
- BIIB $157.46
- Analyst Decision
- VTR Buy
- BIIB Buy
- Analyst Count
- VTR 10
- BIIB 27
- Target Price
- VTR $61.60
- BIIB $252.20
- AVG Volume (30 Days)
- VTR 2.5M
- BIIB 1.5M
- Earning Date
- VTR 10-30-2024
- BIIB 10-30-2024
- Dividend Yield
- VTR 2.96%
- BIIB N/A
- EPS Growth
- VTR N/A
- BIIB 10.05
- EPS
- VTR N/A
- BIIB 11.06
- Revenue
- VTR $4,797,115,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- VTR N/A
- BIIB N/A
- Revenue Next Year
- VTR $7.07
- BIIB N/A
- P/E Ratio
- VTR N/A
- BIIB $14.23
- Revenue Growth
- VTR 10.05
- BIIB N/A
- 52 Week Low
- VTR $41.45
- BIIB $153.62
- 52 Week High
- VTR $67.61
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- VTR 33.04
- BIIB 34.89
- Support Level
- VTR $61.73
- BIIB $158.44
- Resistance Level
- VTR $62.29
- BIIB $162.62
- Average True Range (ATR)
- VTR 1.08
- BIIB 3.52
- MACD
- VTR -0.31
- BIIB 0.66
- Stochastic Oscillator
- VTR 12.40
- BIIB 32.53
About VTR Ventas Inc.
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.